Pfizer Inc.

PFE

Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.

Revenue
−0.43%
EPS
−9.68%
Free cash flow
+20.0%
Total debt
+1.55%

Quarter to September 2026, against a year earlier

27.71 0.14 +0.51%
Market cap
$158.2B
P/E
38.8×
Fwd P/E FY26e
18.7×
Dividend yield
6.24%
F-score
6/9
ROIC
6.19%
Net debt / EBITDA
2.5×
Payout ratio
2.5×

Q3 2026 quarterly report Pfizer described the April 2026 order imposing Section 232 tariffs of up to 100% on imported patented medicines. Read it in the report

Latest quarter Q3 FY2026 · quarter to September 2026

Revenue growth has slowed two quarters running, from 5.40% to −0.40%.

Q3 FY2026 and the seven quarters before it
Quarter Revenue, $m Growth, % Op. margin, % EPS, $
Q3 FY26 16,583 (0.4) 22.1 0.56
Q2 FY26 15,034 2.6 20.4 (0.04)
Q1 FY26 14,451 5.4 27.9 0.47
Q4 FY25 17,557 (1.2) 16.4 (0.29)
Q3 FY25 16,654 (5.9) 23.1 0.62
Q2 FY25 14,653 10.3 25.8 0.51
Q1 FY25 13,715 (7.8) 27.3 0.52
Q4 FY24 17,763 21.9 13.2 0.07

Against the consensus: revenue beat by 2.80% ($16.6B v $16.1B); adjusted EPS beat by $0.15 ($0.87 v $0.72).

Growth is on the same quarter a year earlier, and EPS is diluted. Negative figures in brackets.

Outlook

FY2026 revenue: $62.0 billion–$64.0 billion

Company guidance, Pfizer Inc. results release, 3 November 2026.

Reports Feb 2, 2027 · Q4 FY26 · consensus EPS $0.69

All quarters →

Capital & Financial Ratios $m

Size
Market Cap 158,230
Revenue ttm 63,625
Net income ttm 4,070
Free cash flow ttm 11,786
Net debt Q 48,399
Valuation
P/E 38.8 (above 35: high)
Forward P/E FY26e 18.7
Price / sales 2.5
Forward P/S FY26e Powerpack
Price / FCF 14.3
Price / book 1.8
Financial health
Current ratio Q 1.4
Debt / equity Q 0.7
Interest coverage Q —
Growth
Revenue growth FY26e +0.9%
EPS growth FY26e −5.2% (below 0%: weak)
EPS growth FY27e −3.1% (below 0%: weak)
EPS growth, 5 yrs e −8.6% (below 0%: weak)
Insiders
Net bought 12m 3
Sells 12m 2
Buys 12m 3
Owned by insiders 0.2%

Green and red mark values outside typical ranges; (Q) is the latest quarter; e marks analysts’ estimates, FY26e the fiscal year ending in 2026; n/m is not meaningful, as a P/E on a loss. How we judge →

Compound annual growth

10y 5y 3y
Sales 2.51% 8.48% (14.80%)
Cash Flow (2.25%) (4.07%) (26.33%)
Earnings 1.11% (3.23%) (37.20%)
Book Value 2.93% 6.45% (3.28%)

Valuation

The price implies free cash flow after share-based pay growing 5.2% a year for ten years. It grew −4.5% a year over the last ten.

Implied
5.2%
10 years, reported
−4.5%
Open the model
P/E against its own 10 years 95.98%
10-year low 10-year high
P/S against its own 10 years 21.74%
10-year low 10-year high
P/B against its own 10 years 20.13%
10-year low 10-year high
EV/Sales against its own 10 years 28.06%
10-year low 10-year high
EV/FCF against its own 10 years 52.03%
10-year low 10-year high

Dividends

Yield
6.24%
Annual rate
1.72
Payout ratio
245.7%
Growth, 2018–26
+2.98%/yr
  1. 1.36 ’18
  2. 1.44 ’19 +6
  3. 1.52 ’20 +6
  4. 1.56 ’21 +3
  5. 1.60 ’22 +3
  6. 1.64 ’23 +2
  7. 1.68 ’24 +2
  8. 1.72 ’25 +2
  9. 1.72 ’26 +0
paid change on the year, % Powerpack

Analysts’ price targets Wall Street, collected weekly

Analyst price targets

Analysts’ consensus Wall Street average, updated each weekday

2.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 52,824 52,546 40,825 40,905 41,651 81,288 101,175 59,553 63,627 62,579 63,625 +1.9% 63,127 60,821 55,372 (4.0%)
Gross margin, % 76.67 78.63 77.99 80.31 79.63 62.08 66.05 58.10 71.94 74.33 73.38 (2.3) pt
EBT 8,351 12,305 3,594 11,321 7,036 24,311 34,729 1,058 8,023 7,520 4,259 (1.2%)
EBT margin, % 15.81 23.42 8.80 27.68 16.89 29.91 34.33 1.78 12.61 12.02 6.69 (3.8) pt
Net income 7,246 21,355 11,188 16,056 9,195 22,025 31,407 2,158 8,062 7,812 4,070 +0.8%
Per share, $
Per share, $ Revenue 8.68 8.80 6.95 7.35 7.50 14.51 18.04 10.55 11.23 11.01 11.16 +2.7%
Earnings 1.17 3.57 1.90 2.92 1.73 3.92 5.59 0.38 1.42 1.37 0.71 +1.8%
Cash flow 2.66 2.81 2.70 2.26 2.59 5.82 5.22 1.54 2.25 2.06 2.49 (2.8%)
Capex (0.33) (0.37) (0.36) (0.44) (0.50) (0.48) (0.58) (0.69) (0.51) (0.46) (0.42) +3.9%
Free cash flow 2.33 2.44 2.33 1.82 2.10 5.33 4.64 0.85 1.74 1.60 2.07 (4.1%)
Book value 9.83 12.00 10.86 11.39 11.43 13.83 17.10 15.82 15.62 15.27 15.67 +5.0%
Shares, m 6,089 5,970 5,872 5,569 5,555 5,601 5,608 5,643 5,664 5,683 5,693 (0.8%)
Valuation, ×
Valuation, × P/E 27.57 9.98 22.70 13.16 21.40 15.14 9.20 82.58 18.70 18.31 38.83 23.9
P/S 3.72 4.05 6.14 5.21 4.91 4.07 2.84 2.82 2.36 2.26 2.47 3.8
P/B 3.28 2.97 3.93 3.36 3.22 4.27 3.00 1.88 1.70 1.63 1.76 2.9
EV/Sales 4.18 4.49 6.70 6.25 5.57 4.16 2.97 3.81 3.05 3.08 3.23 4.4
EV/FCF 15.60 16.28 19.97 25.27 20.40 11.63 11.91 56.83 21.49 23.28 18.71 22.3
Cash, $m
Cash, $m Operating cash flow 16,192 16,802 15,827 12,588 14,403 32,580 29,267 8,700 12,744 11,704 14,173 (3.5%)
Capex (1,999) (2,217) (2,136) (2,464) (2,765) (2,711) (3,236) (3,907) (2,909) (2,629) (2,387) +3.1%
Free cash flow 14,193 14,585 13,691 10,124 11,638 29,869 26,031 4,793 9,835 9,075 11,786 (4.8%)
Balance, $m
Balance, $m Working capital 7,834 10,714 18,068 (4,501) 9,147 17,022 9,121 (4,461) 7,363 5,914 13,283 (3.1%)
Net debt 24,236 23,499 22,907 42,504 27,613 7,367 13,097 59,198 43,874 51,199 48,399 +8.7%
Shareholders’ equity 59,840 71,656 63,758 63,447 63,473 77,462 95,916 89,288 88,497 86,775 89,301 +4.2%
Returns, %
Returns, % ROA 4.26 12.41 6.73 9.80 5.69 13.09 16.57 1.00 3.65 3.69 1.95 (0.6) pt
ROIC 9.03 9.01 4.09 3.96 5.66 14.32 20.52 0.54 5.86 6.45 6.19 (2.6) pt
ROE 11.56 32.42 16.48 25.20 14.43 31.19 36.19 2.29 9.03 8.87 4.42 (2.7) pt
People
People Employees 96,500 90,200 92,400 88,300 78,500 79,000 83,000 88,000 81,000 75,000 — (2.8%)
Revenue/emp, $m 0.55 0.58 0.44 0.46 0.53 1.03 1.22 0.68 0.79 0.83 — +4.8%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated Nov 18, 2026

Business profile

Updated

Pfizer is a global biopharmaceutical company that researches, develops, manufactures and sells medicines and vaccines. Founded in 1849 and headquartered in New York City, it is led by Chief Executive Officer Albert Bourla.

Its products span several areas of care. Primary care includes the blood thinner Eliquis, migraine treatments Nurtec ODT/Vydura and Zavzpret, and vaccines such as the Prevnar family and Comirnaty. Pfizer also sells Paxlovid for COVID-19. Its specialty medicines address conditions including inflammatory diseases, rare diseases and certain infections.

Where the money comes from and where it goes Fiscal 2025

Fiscal 2025: revenue by segment, and margins
Biopharma 61,199 97.79%
Other, not broken out 1,380 2.21%
Gross margin 74.33%
Operating margin 22.76%
Pre-tax margin 12.02%

Revenue by segment since 2009

Pfizer Inc. vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NVS Novartis AG $277.7B 28.8× 24.0× FY26e +4.67% (above 0%: growing) −68.81% (below 0%: shrinking) −17.81% (below 0%: shrinking) 75.99% 12.26% Compare
AZN AstraZeneca PLC $272.1B 24.6× 24.2× FY26e +6.70% (above 0%: growing) +23.46% (above 0%: growing) +1.99% (above 0%: growing) 81.82% 27.07% Compare
AMGN Amgen Inc. $237.4B 25.2× 24.0× FY26e +8.45% (above 0%: growing) +19.39% (above 0%: growing) −13.98% (below 0%: shrinking) 73.10% 35.79% Compare
GILD Gilead Sciences, Inc. $207.8B — (loss-making) — (loss-making) +6.83% (above 0%: growing) −20.16% (below 0%: shrinking) +21.13% (above 0%: growing) 81.07% 41.71% Compare
PFE Pfizer Inc. $158.2B 38.8× 18.7× FY26e −0.43% (below 0%: shrinking) −9.68% (below 0%: shrinking) +20.02% (above 0%: growing) 75.71% 22.14%
NVO Novo Nordisk A/S $128.6B 9.8× — +3.87% (above 0%: growing) −17.14% (below 0%: shrinking) −14.75% (below 0%: shrinking) 76.97% 29.06% Compare
BMY Bristol Myers Squibb Company $119.3B 12.9× 12.0× FY26e +6.93% (above 0%: growing) −2.78% (below 0%: shrinking) −35.95% (below 0%: shrinking) 68.28% 19.40% Compare
SNY Sanofi $111.3B 22.8× — +13.89% (above 0%: growing) +8.21% (above 0%: growing) +99.60% (above 0%: growing) 76.16% 28.53% Compare
GSK GSK PLC Sponsored ADR $95.9B 16.4× 15.5× FY26e +3.75% (above 0%: growing) −23.88% (below 0%: shrinking) +62.44% (above 0%: growing) 73.11% 23.93% Compare
Median of peers $168.2B 22.8× 24.0× +6.77% −9.96% −5.99% 76.08% 27.80%

All 21 Drug Manufacturers General stocks →

From the latest earnings call

Updated

  • CEO Albert Bourla said launched and acquired products grew 32% operationally in the quarter, while the legacy Seagen portfolio’s U.S. growth was driven by Padcev.
  • CFO Cecile Guegan said Pfizer raised its 2026 revenue and adjusted earnings guidance following non-COVID product growth and progress on cost improvements.

Analyst rating changes each firm’s latest, last six months

Firm Date Action Rating Target Change
Scotiabank Nov 3, 2026 Target raised — 33.00 —
Cantor Fitzgerald Oct 10, 2026 Target raised Hold 27.00 → 28.00 +3.70%
Bank of America Oct 10, 2026 Target raised Hold 27.00 → 29.00 +7.41%
JPMorgan Oct 10, 2026 Target raised Hold 28.00 → 30.00 +7.14%

Largest institutional holders 13F, quarter to Jun 30, 2026

Held by institutions 66.78%
Held by the ten largest 34.47%
Holder Shares Stake Change
Vanguard 552.48m 9.69% +6.53m
BlackRock 529.67m 9.29% +31.41m
State Street 307.09m 5.39% +5.50m
Geode Capital Management 135.28m 2.37% +1.71m
Fisher Investments 109.07m 1.91% +4.10m
Morgan Stanley 96.35m 1.69% +3.66m
Norges Bank 61.51m 1.08% +61.51m
Northern Trust 59.08m 1.04% −2.94m
BNY 57.88m 1.02% +4.00m
MFS Investment Management 56.55m 0.99% −360.82k
13F filings for the quarter to 30 June 2026: long positions in US-listed shares reported by managers with $100m or more, ~45 days after the quarter.

Pay and ownership Proxy statement filed Mar 12, 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 27.59m 33.71m 86.00
2024 24.65m 38.52m 86.00
2023 21.56m (62.15m) 88.00
2022 33.02m 5.66m 149.00
2021 24.35m 115.18m 167.00
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement

Pfizer Inc. (PFE) Latest News

What happened

  1. Deal Pfizer completed its acquisition of Metsera, adding long-acting injectable obesity drug candidates to its portfolio.
  2. Legal Arbutus and Genevant filed new lipid nanoparticle patent lawsuits against Pfizer in Japan and added a patent to their Canadian case against Pfizer and BioNTech.
  3. Capital Pfizer agreed to receive up to $1.5 billion from Blackstone Life Sciences for berobenatide development through 2028, while retaining ownership and control.
  4. Results Pfizer reported that ELREXFIO improved progression-free survival in a Phase 3 trial, with 68% of patients remaining progression-free at 18 months.
  5. Guidance Pfizer reported nearly flat third-quarter revenue of $16.6 billion and raised its 2026 revenue outlook to $62 billion–$64 billion.
10 more headlines
All PFE news, as stories →

PFE metrics, ten years each

stockrow.com/PFE · Data as of Nov 18, 2026 · For information only; not investment advice. · © 2026 stockrow.com